Showing 3291-3300 of 8741 results for "".
- Study: Head and Neck Melanomas Show Unique Patternshttps://practicaldermatology.com/news/study-head-and-neck-melanomas-show-unique-patterns/2470807/A recent study published in the Journal of the American Academy of Dermatology reports that cutaneous melanomas located on the head and neck (CHNM) exhibit distinct clinicopathological features and treatment outcomes compared to melanomas at other anatomical sites (CMOS). Researc
- Neurotrimin Identified as Key Target for Keloid Treatment: Analysishttps://practicaldermatology.com/news/neurotrimin-identified-key-target-keloid-treatment-analysis/2470778/Researchers for a new genetic study have identified seven proteins as potential drug targets for the treatment of keloids, with neurotrimin (NTM) emerging as a particularly significant finding. Publishing in the Journal of Investigative Dermatology, the study design employed a two-sample M
- New Computational System Evaluates Vitiligo Repigmentation Rateshttps://practicaldermatology.com/news/new-computational-system-evaluates-vitiligo-repigmentation-rates/2470766/A research team from Shenzhen People’s Hospital have developed a computational system for evaluating repigmentation rates in vitiligo patients, according to a new paper in the Journal of Investigative Dermatology. The retrospective study, conducted from June 2019 to November 2022
- National Rosacea Society Introduces Informational Postcardhttps://practicaldermatology.com/news/national-rosacea-society-introduces-informational-postcard/2470763/The National Rosacea Society (NRS) announced today that it has released a new educational postcard to raise awareness about rosacea, a chronic skin condition affecting over 16 million Americans. Titled “Rosacea: A Common Disease, Uncommonly Treated,” the resource is designed for d
- FDA Approves Nemluvio for Moderate-to-Severe Atopic Dermatitishttps://practicaldermatology.com/news/fda-approves-nemluvio-moderate-severe-atopic-dermatitis/2470663/Galderma’s Nemluvio® (nemolizumab) has received FDA approval for moderate-to-severe atopic dermatitis in patients aged 12 and older, offering a novel treatment option targeting IL-31. According to a press release from Galderma, the approval follows results from the phase III ARCADIA trial
- Advanced Neuroprotein Technique Linked with Improved Aesthetic Resultshttps://practicaldermatology.com/news/advanced-neuroprotein-technique-linked-improved-aesthetic-results/2468758/A study evaluating the use of botulinic neuroprotein combined with low molecular weight hyaluronic acid (LMWHA) and lyophilized amino acids in a single syringe showed enhanced outcomes in aesthetic treatments. The study included patients treated with a single injection session. According t
- OLYMPIA 1: Nemolizumab Shows Improvements in Prurigo Nodularis Symptomshttps://practicaldermatology.com/news/olympia-1-nemolizumab-shows-improvements-prurigo-nodularis-symptoms/2468705/Results from a multicenter phase 3 clinical trial indicated that nemolizumab monotherapy significantly reduces pruritus and nodular lesions in adults with moderate to severe prurigo nodularis (PN). Researchers for the OLYMPIA 1 trial evaluated the efficacy and safety of nemolizumab in 286
- Xylazine Wounds: Chronicity Linked to Necrosishttps://practicaldermatology.com/news/xylazine-wounds-chronicity-linked-necrosis/2468631/Xylazine-associated wounds frequently present on extremities with necrotic wound beds and increase in severity with chronicity, according to a systematic case series published in JAMA Dermatology. The case series was conducted across three academic hospitals looking at clinical characteris
- Study Links Severe AD With Need for Surgery in Glaucoma Patientshttps://practicaldermatology.com/news/study-links-severe-ad-need-surgery-glaucoma-patients/2468562/Patients suffering from both severe atopic dermatitis (AD) and glaucoma are increasingly likely to need surgical intervention for the glaucoma depending on the severity of their AD, according to a new Journal of Glaucoma study. “Association of Atopic Dermatitis and Risk of Glaucoma Surgery
- T-VASI and F-VASI Shown Reliable in Nonsegmental Vitiligo Assessmenthttps://practicaldermatology.com/news/t-vasi-and-f-vasi-shown-reliable-nonsegmental-vitiligo-assessment/2468550/New research confirmed that the Total Vitiligo Area Scoring Index (T-VASI) and the Facial VASI (F-VASI) are reliable and valid tools for measuring meaningful improvement in patients with nonsegmental vitiligo. The study, published in JAMA Dermatology, included 164 adult participa